Title |
Primary myelofibrosis: current therapeutic options
|
---|---|
Published in |
Hematology Transfusion and Cell Therapy, April 2016
|
DOI | 10.1016/j.bjhh.2016.04.003 |
Pubmed ID | |
Authors |
Paula de Melo Campos |
Abstract |
Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal myeloid expansion, followed by progressive fibrous connective tissue deposition in the bone marrow, resulting in bone marrow failure. Clonal evolution can also occur, with an increased risk of transformation to acute myeloid leukemia. In addition, disabling constitutional symptoms secondary to the high circulating levels of proinflammatory cytokines and hepatosplenomegaly frequently impair quality of life. Herein the main current treatment options for primary myelofibrosis patients are discussed, contemplating disease-modifying therapeutics in addition to palliative measures, in an individualized patient-based approach. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 27 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 6 | 22% |
Student > Bachelor | 5 | 19% |
Student > Doctoral Student | 4 | 15% |
Other | 3 | 11% |
Student > Ph. D. Student | 2 | 7% |
Other | 4 | 15% |
Unknown | 3 | 11% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 44% |
Immunology and Microbiology | 2 | 7% |
Agricultural and Biological Sciences | 2 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Biochemistry, Genetics and Molecular Biology | 1 | 4% |
Other | 4 | 15% |
Unknown | 5 | 19% |